scholarly journals Phage therapy with mycobacteriophage as an alternative against antibiotic resistance produced by Mycobacterium tuberculosis

Bionatura ◽  
2020 ◽  
Vol 5 (1) ◽  
pp. 1078-1081
Author(s):  
Pamela Rodríguez H ◽  
Angie Changuán C ◽  
Lizbeth X. Quiroz

Bacteriophages are considered a genetic strategy to combat pathogen bacteria that show resistance to antibiotics. Molecular biology has implemented various control measures to deal with bacteria; the application of bacteriophage directly to tuberculosis viruses is a technological tool currently using. Mycobacteriophage is a type of virus that infects mycobacterium hosts. Because most of them have been genetically modified, they are providing insights into viral diversity. Furthermore, phage therapy is potentially a way to improve the treatment of bacterial infections strictly mediated by bacteriophages of lysogenic and lytic type. Genetic modifications are an essential factor for the development of future phage therapy applications to control the diseases caused by Mycobacterium tuberculosis. This review is about the mycobacteriophages to control the antimicrobial resistance caused by Mycobacterium tuberculosis thought some applications of phage therapy.

2020 ◽  
Vol 2 (3) ◽  
pp. 78-79
Author(s):  
Roberto Badaro

Bacteriophages are viruses that infect and parasitize bacteria. The current increase in the incidence of antibiotic resistance in human bacteria has favoredthe study of phages as a therapeutic alternative (phage therapy). Phage therapy is defined as the administration of virulent phages directly to a patient to lyse the bacterial pathogen that is causing a clinically severe infection. The ideal route of administration and modification of bacteriopaghes genetically to deactivate bacterial resistance genes is the next future to antibiotic recovery sensitivity of MDR organisms.


10.3823/846 ◽  
2020 ◽  
Vol 10 (2) ◽  
Author(s):  
Abdelraouf A Elmanama ◽  
Suhaila Al-Sheboul ◽  
Renad I Abu-Dan

Abstract Pseudomonas aeruginosa threatens patient’s care. It is considered as the most complicated health care associated pathogen to be eliminated from infection site. The biofilm forming ability of P. aeruginosa, being a major virulence factor for most pathogenic microorganism, protects it from host immunity and contribute to antibiotic resistance of this organism. It is estimated that about 80% of infectious diseases are due to biofilm mode of growth. Biofilm forming ability of bacteria imparts antimicrobial resistance that leads to many persistent and chronic bacterial infections. The world is becoming increasingly under the threat of entering the “post-antibiotic era”, an era in which the rate of death from bacterial infections is higher than from cancer. This review focus on P. aeruginosa biofilm forming ability; definition, developmental stages, and significance. In addition, the quorum sensing and the antibiotic resistance of this pathogen is discussed. Keywords: Biofilm; bacterial adhesion; Pseudomonas aeruginosa; antimicrobial resistance; quorum sensing.


Antibiotics ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 714 ◽  
Author(s):  
Zheng Jiang ◽  
Junwei Wei ◽  
Yunxiang Liang ◽  
Nan Peng ◽  
Yingjun Li

Antibiotic resistance is becoming the biggest threat to global health. At the same time, phage therapy is witnessing a return of interest. The therapeutic use of bacteriophages that infect and kill bacteria is a suitable strategy to combat antibiotic resistance. Furthermore, bacteriophages are increasingly used in combination with standard antibiotics against drug-resistant pathogens. Interestingly, we found that the engineered mycobacteriophage phAE159 and natural phage D29 cannot infect the Mycobacterium tuberculosis in the presence of kanamycin, hygromycin or streptomycin, but the phage infection was not affected in the presence of spectinomycin. Based on a series of studies and structural analysis of the above four aminoglycoside antibiotics, it could be speculated that the amino sugar group of aminoglycoside might selectively inhibit mycobacteriophage DNA replication. Our discovery that broad-spectrum antibiotics inhibit phage infection is of great value. This study will provide guidance for people to combine phage and antibiotics to treat M. tuberculosis.


mBio ◽  
2017 ◽  
Vol 8 (4) ◽  
Author(s):  
Roderick M. Card ◽  
Shaun A. Cawthraw ◽  
Javier Nunez-Garcia ◽  
Richard J. Ellis ◽  
Gemma Kay ◽  
...  

ABSTRACT The chicken gastrointestinal tract is richly populated by commensal bacteria that fulfill various beneficial roles for the host, including helping to resist colonization by pathogens. It can also facilitate the conjugative transfer of multidrug resistance (MDR) plasmids between commensal and pathogenic bacteria which is a significant public and animal health concern as it may affect our ability to treat bacterial infections. We used an in vitro chemostat system to approximate the chicken cecal microbiota, simulate colonization by an MDR Salmonella pathogen, and examine the dynamics of transfer of its MDR plasmid harboring several genes, including the extended-spectrum beta-lactamase bla CTX-M1. We also evaluated the impact of cefotaxime administration on plasmid transfer and microbial diversity. Bacterial community profiles obtained by culture-independent methods showed that Salmonella inoculation resulted in no significant changes to bacterial community alpha diversity and beta diversity, whereas administration of cefotaxime caused significant alterations to both measures of diversity, which largely recovered. MDR plasmid transfer from Salmonella to commensal Escherichia coli was demonstrated by PCR and whole-genome sequencing of isolates purified from agar plates containing cefotaxime. Transfer occurred to seven E. coli sequence types at high rates, even in the absence of cefotaxime, with resistant strains isolated within 3 days. Our chemostat system provides a good representation of bacterial interactions, including antibiotic resistance transfer in vivo. It can be used as an ethical and relatively inexpensive approach to model dissemination of antibiotic resistance within the gut of any animal or human and refine interventions that mitigate its spread before employing in vivo studies. IMPORTANCE The spread of antimicrobial resistance presents a grave threat to public health and animal health and is affecting our ability to respond to bacterial infections. Transfer of antimicrobial resistance via plasmid exchange is of particular concern as it enables unrelated bacteria to acquire resistance. The gastrointestinal tract is replete with bacteria and provides an environment for plasmid transfer between commensals and pathogens. Here we use the chicken gut microbiota as an exemplar to model the effects of bacterial infection, antibiotic administration, and plasmid transfer. We show that transfer of a multidrug-resistant plasmid from the zoonotic pathogen Salmonella to commensal Escherichia coli occurs at a high rate, even in the absence of antibiotic administration. Our work demonstrates that the in vitro gut model provides a powerful screening tool that can be used to assess and refine interventions that mitigate the spread of antibiotic resistance in the gut before undertaking animal studies. IMPORTANCE The spread of antimicrobial resistance presents a grave threat to public health and animal health and is affecting our ability to respond to bacterial infections. Transfer of antimicrobial resistance via plasmid exchange is of particular concern as it enables unrelated bacteria to acquire resistance. The gastrointestinal tract is replete with bacteria and provides an environment for plasmid transfer between commensals and pathogens. Here we use the chicken gut microbiota as an exemplar to model the effects of bacterial infection, antibiotic administration, and plasmid transfer. We show that transfer of a multidrug-resistant plasmid from the zoonotic pathogen Salmonella to commensal Escherichia coli occurs at a high rate, even in the absence of antibiotic administration. Our work demonstrates that the in vitro gut model provides a powerful screening tool that can be used to assess and refine interventions that mitigate the spread of antibiotic resistance in the gut before undertaking animal studies.


2019 ◽  
Vol 13 (06) ◽  
pp. 504-509 ◽  
Author(s):  
Çiğdem Arabacı ◽  
Tuba Dal ◽  
Tuğcan Başyiğit ◽  
Neslihan Genişel ◽  
Rıza Durmaz

Introduction: Carbapenem-resistant Klebsiella pneumoniae are a major problem. We aimed to investigate carbapenemase-encoding genes and transferable mcr-1 genes among 57 carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates from hospitalized patients. Methodology: Antibiotic susceptibility tests were performed by Phoenix (BD). Results for ertapenem and colistin were confirmed by gradient diffusion and microdilution methods. Carbapenemase and mcr-1 genes were investigated by Polymerase Chain Reaction (PCR). Results: Thirty-two (56.14%) isolates were from intensive care units (ICU). Antibiotic resistance rates by Phoenix: 52.63% for amikacin; 73.69% trimethoprim sulfamethoxazole; 91.23% cefepime; 82.46% tigecycline; 59.65% colistin. Carbapenemases positivity: 82.45% (47) for blaOXA-48, 40.35% (23) blaOXA-55, 3.50% (2) blaOXA-51, 1.75% (1) blaOXA-23, 1.75% (1) blaOXA-24, 1.75% (1) blaIMP. blaOXA-58, blaKPC, blaNDM-1, and blaVIM were not detected. Twenty (35.08%) isolates had both blaOXA-48 and blaOXA-55. Three isolates were mcr-1 (+) and blaOXA-48 (+). One mcr-1 (+) isolates was blaOXA-51 (+). One colistin sensitive isolate determined by Phoenix, was found colistin resistant by microdilution. Conclusion: OXA-48 and OXA-55 co-harboring isolates and mcr-1 gene (+) isolates were spreading. Automated colistin susceptibility results should be confirmed by microdilution method. Resistance mechanisms in Enterobacteriaceae should be determined and the isolates should be monitored by molecular epidemiological methods. Effective infection control measures will contribute to reduce risk of antibiotic resistant bacterial infections and dissemination of antibiotic resistance.


Author(s):  
Marissa Gittrich ◽  
Yunxiao Liu ◽  
Funing Tian ◽  
Audra Crouch ◽  
Ho Bin Jang ◽  
...  

: As antibiotic resistance undermines efforts to treat bacterial infections, phage therapy is being increasingly considered as an alternative in clinical settings and agriculture. However, a major concern in using phages is that pathogens will develop resistance to the phage. Due to the constant evolutionary pressure by phages, bacteria have evolved numerous mechanisms to block infection. If we determine the most common among them, we could use this knowledge to guide phage therapeutics. Here we compile data from 88 peer-reviewed studies where phage resistance was experimentally observed and linked to a bacterial gene, then assessed these data for patterns. In total, 141 host genes were identified to block infection against one or more of 80 phages (representing five families of the Caudovirales) across 16 microbial host genera. These data suggest that bacterial phage resistance is diverse, but even well-studied systems are understudied, and there are gaping holes in our knowledge of phage resistance across lesser-studied regions of microbial and viral sequence space. Fortunately, scalable approaches are newly available that, if broadly adopted, can provide data to power ecosystem-aware models that will guide harvesting natural variation towards designing effective, broadly applicable phage therapy cocktails as an alternative to antibiotics.


Author(s):  
Aditi Deepak Gupta ◽  
Praful S. Patil

Antimicrobial resistance is a slow-growing phenomenon that could even be a reason for a future pandemic. Due to inappropriate diagnosis and consumption of antibiotics, the bacteria have become resistant to the antibiotics used. In the era of COVID-19, this blind consumption of antibiotics has rapidly increased due to the period of quarantine and fear of the disease. Ligue to the fear of the pandemic, especially in ru, rural areas, many patients avoid going to the hospital and consuming antibiotics without any prescription. Various retrospective studies have shown a relationship between bacterial co-infection and AMR, which is increased in the era of COVID-19. Also, the secondary bacterial infections associated with the pandemic of COVID-19 have added to the risk of antimicrobial resistance. The viral effect on the respiratory system is favorable for bacterial infection, as in the case of COVID-19 affecting the respiratory tract followed by co-bacterial infection in some cases. COVID-19 has affected AMR in many aspects. Proper antibiotic resistance tests should be performed before prescribing any antibiotics to the patient to reduce the chances of AMR, especially in such an obnoxious situation of COVID-19. This crucially calls for a brand new and effective plan of action to attenuate the influence of the pandemic on antimicrobial resistance. Statistics of various countries in matters of antimicrobial resistance have shown an increase in AMR due to the concentration of health workers, researchers, and population on the pandemic associated with COVID-19. This calls for the necessity to aware the population worldwide about antimicrobial resistance and how it could be a hidden menace in the future and could probably prove to be a matter of concern as it would worsen the condition of the patients in a particular disease and would decrease the various possible aspects of the treatment especially in case of treatment based on antibiotics.


2020 ◽  
Vol 42 (6) ◽  
pp. 6-11
Author(s):  
Michael J Love ◽  
Renwick C J Dobson ◽  
Craig Billington

The growing prevalence of antibiotic resistance is a global crisis. It is predicted that by 2050, antibiotic resistance-related deaths will exceed by 10 million per year. Thus, there is an urgent need for alternative strategies that can either replace or supplement antibiotic use. Bacteriophages and their encoded lytic proteins, called endolysins, have both shown promise as antibiotic alternatives. Bacteriophages were first investigated as therapeutics nearly a century ago, but the success of antibiotics led to phage therapy being largely abandoned in Western medicine until recently. While sporadic reports of life-saving successes in the ad hoc use of phage therapy have emerged, properly designed, robust clinical trials and clear regulatory guidelines are required before the true potential of phage therapy can be realized. In addition, despite endolysin research still being in its infancy, the early successes of endolysin-based therapeutics already entering clinical trials are an exciting glimpse into the future. No stone can be left unturned in the discovery and development of novel therapeutics if we are to ensure a future supply of effective treatments for bacterial infections.


2021 ◽  
Author(s):  
Chirag Choudhary ◽  

The idea of using a virus to kill bacteria may seem counterintuitive, but it may be the future of treating bacterial infections. Before the COVID-19 pandemic, one of the most frightening biological agents were so-called “superbugs” – antibiotic resistant bacteria – which could not be treated with conventional therapeutics. When antibiotics were first developed, they were hailed as a panacea. A panacea they were not.


2020 ◽  
Author(s):  
Jaden Bhogal ◽  

Antimicrobial resistance (AMR) is the ability of a microorganism to resist antimicrobial treatments against it, resulting in persisted and oftentimes lethal infection in individuals. The World Health Organization (WHO) predicts that AMR has the potential to skyrocket into one of the largest global health issues humanity has ever faced. In their 2018 fact sheet, they mention how it will cause 10 million deaths annually by 2050, as well as US $100 trillion in economic losses (World Health Organization, 2018). AMR has greatly reduced the efficacy of antibiotics in treating bacterial infections. According to Benno. H. ter Kuile and colleagues from the Department of Molecular Biology and Microbial Food Safety at the University of Amsterdam, most AMR is caused by practices in the agricultural industry, making it an extremely complex and difficult problem to solve regardless of its urgency (ter Kuile, Kraupner & Brul, 2016). However, Kaitlyn Kortright and colleagues from Yale University and the Yale School of Medicine, posit that phage therapy - a novel medical treatment with renewed interest in Western medicine - has large potential as an effective solution for antimicrobial resistance in bacteria (Kortright, Chan, Koff & Turner, 2019).


Sign in / Sign up

Export Citation Format

Share Document